Lakewood-Amedex Biotherapeutics Inc. (LABT) stock
LABTNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 16, 2026
$0.21−0.00 (-2.23%)
Close on Nov 17, 2026Market cap $508.30KP/E –Yield –
Lakewood-Amedex Biotherapeutics r&d expenses
Research and development expenses are spending on new products and technology.
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $733.10K | +399.0% |
| Q2 FY2026 | Jun 30, 2026 | $503.02K | +196.4% |
| Q1 FY2026 | Mar 31, 2026 | $182.15K | – |
| Q3 FY2025 | Sep 30, 2025 | $752.93K | – |
| Q2 FY2025 | Jun 30, 2025 | $146.90K | – |
| Q1 FY2025 | Mar 31, 2025 | $169.70K | – |
See a number that looks wrong?